WASHINGTON (dpa-AFX) - Seattle Genetics Inc (SGEN) and Genmab A/S (GNMSF.PK)
on Wednesday entered into an additional antibody-drug conjugate collaboration.
Under the new agreement, Genmab will pay an upfront fee of $11 million for
Genmab A/S (OTC:GNMSF)
Q2 2014 Earnings Conference Call
August 13, 2014 12:00 PM ET
Jan G. J. van de Winkel – President and Chief Executive Officer
David A. Eatwell – Executive Vice President & Chief Financial...
LONDON (dpa-AFX) - GlaxoSmithKline plc (GSK, GSK.L) and Denmark-based
biotechnology company Genmab A/S (GMXAY.PK, GNMSF.PK) announced that the
European Commission or EC has granted marketing authorization for a new
indication for the use of...
Welcome to the latest edition of our weekly EuroBiotech Report. With the battle for investor support in the AbbVie-Shire takeover tug of war heating up, the Ireland-headquartered biopharma has played up its European roots and rare position in the...
LONDON (dpa-AFX) - GlaxoSmithKline plc (GSK, GSK.L) and Genmab A/S said
Thursday that the U.S. Food and Drug Administration has approved a Supplemental
Biologic License Application for the use of Arzerra, a CD20-directed monoclonal
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.